Stocksigma LogoStocksigma Logo

Cohance Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)

■ Revenue: 477 (-14.2% YoY | +12.9% QoQ) ■ EBITDA: 35.4 (-70.7% YoY | +2950.0% QoQ) ■ EBITDA Margin (%): 7.4 (-1435 bps YoY | +715 bps QoQ) ■ PAT: 15.2

Cohance Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)

Cohance Lifesciences Ltd · Outcome · 06 Nov 2026, 11:18 pm

Cohance Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 477 (-14.2% YoY | +12.9% QoQ) ■ EBITDA: 35.4 (-70.7% YoY | +2950.0% QoQ) ■ EBITDA Margin (%): 7.4 (-1435 bps YoY | +715 bps QoQ) ■ PAT: 15.2 (-79.5% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.38 (-80.3% YoY | Loss to Profit QoQ)

Original exchange filing (PDF)

More announcements from Cohance Lifesciences Ltd

All Cohance Lifesciences Ltd announcements